瑞士Idorsia公司10月26日宣布：推进失眠药用于孤独症谱系障碍的新研发
10 月 26 日，总部位于瑞士阿尔施维尔的 Idorsia公司宣布，将推进其失眠药物达利雷生用于孤独症谱系障碍的新研发项目。在一项针对儿童失眠障碍的二期研究中，研究人员观察到，除了睡眠指标明显改善之外，服用 50毫克达利雷生的孤独症谱系障碍或具有亚临床特征的参与者，在情感与行为、认知与日常活动方面也出现了意想不到的改善模式。结合公司内部研究数据与已发表的科学文献，以及达利雷生独特的作用机制，公司认为有理由进一步探索其在孤独症谱系障碍治疗中的应用。公司表示，正在并行开发专门的制剂，并与全球卫生主管部门讨论研发项目的设计，包括拟研究的剂量，更多细节预计在 2027年上半年公布。首席执行官罗兰·万德勒表示，这一来自临床研究的观察，为公司开辟了一条全新的科学路径，而孤独症谱系障碍目前的治疗选择仍然非常有限，探索潜在的新治疗方法对患者及其家庭具有特殊意义。需要提醒读者的是，目前的发现仍属于早期研究信号，距离真正成为获批疗法还有很长的路要走：后续研究需要更大规模、更严格的临床试验来验证效果与安全性，患者家庭不应自行调整用药，而应遵从医生的专业意见。
Switzerland's Idorsia Announces on October 26: Advancing New Development of Its Insomnia Drug for Autism Spectrum Disorder
On October 26, Idorsia, headquartered in Allschwil, Switzerland, announced that it will advance a new development programme for its insomnia drug daridorexant in autism spectrum disorder. In a Phase 2 study in children with insomnia disorder, researchers observed that, in addition to marked improvements in sleep measures, participants with autism spectrum disorder or subclinical features who took 50 mg of daridorexant also showed unexpected patterns of improvement in emotion and behaviour, cognition and daily activities. Combining internal company research data with published scientific literature, and daridorexant's unique mechanism of action, the company believes there is reason to further explore its application in treating autism spectrum disorder. The company said it is developing a dedicated formulation in parallel and discussing the design of the development programme, including the doses to be studied, with health authorities worldwide, with more details expected in the first half of 2027. Chief executive Roland Wandeler said this observation from clinical research opens an entirely new scientific avenue for the company, while treatment options for autism spectrum disorder remain very limited, so exploring potential new therapies has special significance for patients and their families. Readers should note that the current findings are still an early research signal, and there is a long road to an approved therapy: follow-up research needs larger, more rigorous clinical trials to verify efficacy and safety, and patients' families should not adjust medication on their own but follow doctors' professional advice.
来源：GSM·美国（原文链接）
图片来源：实验室研究人员（资料图）（资料图）。摄影：Photo Credit: James Gathany Content Providers: CDC/ Douglas E. Jordan，Public domain，取自 Wikimedia Commons。Photo: Laboratory researcher (file photo) (file photo). Credit: Photo Credit: James Gathany Content Providers: CDC/ Douglas E. Jordan, Public domain, via Wikimedia Commons.
